Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 52 matches for

The collective force of cancer research, outreach and care across the city of Oxford, translating discoveries into better care for cancer patients.

New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes

A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

OCION: In conversation with Tamsin Cargill

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump Prime awardee - Dr. Tamsin Cargill - to discuss her research.

Pancreatic cancer immune map provides clues for precision treatment targeting

New research - published today in Nature Communications - shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.

OCION: In conversation with Adán Pinto-Fernández

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Dr. Adán Pinto-Fernández to discuss his research.

University of Oxford unveils new vaccine development partnership

Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.

2024 OCION Pump Prime Awardees Named

Congratulations to the 2024 OCION Pump Prime Awardees, funded by the CRUK Oxford Centre and NIHR Oxford BRC

COMBATcancer at the HIPP Summer School 2024

Aleksandra Dzhoneva - Postdoctoral Scientist- shares her experience at the HIPP Summer School 2024, which she attended to present research as part of the COMBATcancer consortium. Her attendance was fully funded by Oxford Cancer.

Dr Bo Sun awarded Future Leaders Grant

The three-year £225,000 grant from The Brain Tumour Charity will fund research into whether it's possible to use T-cells to track and detect gliomas.

OCION: In conversation with Alfred Zippelius

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Alfred Zippelius to discuss his research.

OCION: In conversation with Ignacio Melero

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Ignacio Melero to discuss his research.

The great escape artist – how tracking co-evolution could improve immunotherapy

Tumour cells escaping the immune system is a major cause of resistance to cancer immunotherapy. So how can we stop it? Audrey Gérard sat down with CRUK to discuss...

OCION: In conversation with Felipe Galvez-Cancino

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Felipe Galvez-Cancino, who has recently joined the Nuffield Department of Medicine, to discuss his research.

OCION: In conversation with Dave Withers

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor David Withers, who recently moved to Oxford, to discuss his research.

Immunotherapy: finding hidden ways to treat cancer

Giamp Valenzano, a DPhil in Cancer Science student, joins forces with Oxford Sparks to deliver a video explaining how his research on immunotherapy aims to help treat cancer

Oxford Cancer Immuno-Oncology Network 2024 Symposium

Fantastic day of immuno-oncology talks and networking at this years' annual OCION Symposium!

Immune cells hunt down cancer around the body – discovery could lead to personalised treatments for advanced breast cancer

Scientists have discovered the key features of immune B cells which make them successful at targeting tumours – including when cancer has spread to a different part of the body.

New study reveals how T cells gain and maintain tolerance to gut bacteria

The immune system in the intestine maintains a careful balance, tolerating our long-term resident (commensal) gut bacteria while defending against invading pathogens. Under certain circumstances, dysregulation of our intestinal immune response to commensal and pathogenic microbes can drive inflammatory disease.

OCION: In conversation with Tim Elliott

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to realise the long-term curative benefits of immunotherapy for more patients by devising new treatments, broadening the impact of existing treatments, and reducing side effects. We sat down with Director, Tim Elliott, to discuss further.

£1.7 million for vaccine to prevent lung cancer

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

OCION Funding Scheme: In conversation with Alistair Easton

The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardee, Alistair Easton, to discuss what research the fund will enable him to carry out.

Load More